INTRODUCTION
The discovery of novel antiviral therapies 1 and the continuing development of annual vaccines 2 have not yet led to an adequate treatment for influenza virus (Flu a ), an important pathogen responsible for both yearly seasonal epidemics and more extensive global pandemics. This issue was clearly evident during the unexpected emergence of the 2009 H1N1 pandemic strain by the reassortment of genes from human, pig, and bird's H1N1 viruses. 3 This last pandemic, together with the on-going circulation of highly pathogenic avian H5N1 strains and the recent emergence of the H7N9 virus, a new reassortant of avian origin isolated in China and associated with severe respiratory disease with 40% of mortality, 4 which could potentially adapt for human-to-human transmission, 5 highlighted the vulnerability of the world population to novel Flu strains. Although vaccination remains the main prophylactic strategy for controlling Flu infection, during the lagging time needed to produce a new vaccine and even during typical epidemic years, since vaccination does not prevent completely Flu infection, our only weapon against pandemic Flu are antivirals.
Currently, only two classes of drugs have been approved by FDA for the treatment of Flu: the neuraminidase inhibitors oseltamivir and zanamivir, that are active on both influenza A (FluA) and influenza B (FluB) viruses, and the M2 channel blockers amantadine and rimantadine, whose spectrum of action is limited to FluA. Since Flu viruses have a high mutation rate, a major problem with both classes of drugs is the emergence of drug-resistant strains. Clearly, next-generation antivirals are needed to efficiently combat Flu, preferably with an innovative mechanism of action.
The viral RNA-dependent RNA polymerase (RdRP) provides an attractive target [6] [7] [8] [9] given its functional essentiality for viral replication and involvement in virus pathogenicity. [10] [11] [12] RdRP could be ideal for the development of new antivirals, since it is highly conserved among FluA, B, and C 13 while no homologue has been found in mammalian cells. 6, 8, 13 RdRP is a complex of three subunits, polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase basic protein 2 (PB2), which are responsible for both transcription and replication. 10, [14] [15] [16] The assembly of the three subunits into functional viral RdRP is an essential step for influenza virus RNA synthesis and virus replication. [17] [18] [19] Thus, the interference with its correct assembly through protein-protein interaction (PPI) inhibitors represents an attractive strategy to inhibit this enzyme. Although very challenging, [20] [21] [22] [23] the feasibility of such an approach has been demonstrated by the identification of antiviral peptides able to inhibit the PA-PB1 interaction. [24] [25] [26] [27] The recent publication of two crystallographic structures of a truncated form of PA bound to a PB1-derived peptide has shown that relatively few residues drive the binding of PB1 to PA, 28, 29 suggesting the potential for small molecule-mediated inhibition. The proof-of-principle that the PA-PB1 interaction can be indeed disrupted also by small molecular-weight compounds was recently provided by us [30] [31] [32] and few other authors. 33, 34 In our SBDD approach, an in silico screening of 3 million small molecules from the ZINC database, performed using one of the available crystal structures, 28 led to the identification of 32 virtual hits which were then evaluated in vitro for their ability to disrupt the PA-PB1 interaction.
Five of them inhibited this interaction specifically and in a dose-dependent manner with IC50 values in the micromolar range, 31 making all of them worthy of further investigation.
In the present study, we attempted the structural optimization of thiophene-3-carboxamide derivative 1 ( Figure 1 , compound 10 in reference 31). This compound was able to disrupt the PA-PB1 interaction in vitro with an IC50 of 90.7 µM and, even though it exhibited antiviral activity against FluA in infected cells at EC50 values slightly higher than 100 µM, its peculiar mechanism of action, coupled with the lack of cytotoxicity (CC50 > 250 µM) evaluated in two cell lines (MardinDarby canine kidney (MDCK) and HEK 293T), made this compound a valid starting point. In an attempt to improve the ability to disrupt the PA-PB1 interaction and achieve a better anti-Flu activity, while maintaining the lack of toxicity, a number of structural modifications were undertaken synthesizing a series of analogues (compounds 2-36 in Table 1 ). Herein we report on their design, synthesis, and biological evaluation.
DESIGN OF THIOPHENE-3-CARBOXAMIDE DERIVATIVES
Compound 1 is made up of a tetrahydrocycloheptathiophene ring bearing at both the C-2 and C-3
positions an amide moiety functionalized with an aromatic ring ( Figure 1 ). The attention was mainly focused on modifying the o-fluorophenyl ring placed at the C-2 position, due to the higher synthetic accessibility. In particular, following the classical medicinal chemistry strategy, the ofluoro atom was eliminated (compound 2), shifted as in its positional isomers (compounds 3 and 4)
as well as replaced by chlorine atom (compounds 5 and 6); dihalogen derivatives (compounds 7 and 8) were also prepared. A cyclohexyl ring replaced the phenyl group in derivative 9. Then, the phenyl/cyclohexyl ring was spaced by inserting one or two methylenic units (compounds 10-16).
Additional derivatives were synthesized following the suggestions of a computational study performed using the same method that recently led us to identify a number of inhibitors of the PA/PB1 binding. 31 The FLAP (Fingerprints for Ligands and Proteins) structure based virtual screening algorithm was recently used to identify a number of inhibitors of the PA/PB1 binding, using the x-ray crystallographic structure of the PA/PB1 complex 28 as a template.
Additional derivatives were synthesized following the suggestions of a computational study, performed using the Fingerprints for Ligands and Proteins (FLAP) algorithm. This method recently led us to identify a number of inhibitors of the PA/PB1 binding, 31 using the x-ray crystallographic structure of the PA/PB1 complex 28 as a template. Although FLAP is not a classical docking procedure based on energy minimization, it allows to evaluate hypotheses on the binding mode of the screened compounds looking for the best overlap of the GRID Molecular Interaction Fields (MIFs), calculated for the protein cavity and for the ligand. [35] [36] [37] Hydrophobic, hydrophilic and hydrogen-bond donor and acceptor interactions are considered. Since GRID MIFs are energy related, a high similarity between the MIFs of the protein and the ligands indicates an energy favored binding mode.
Our previous study revealed the importance of hydrophobic interactions in the ligand-PA recognition process. 31 The green spots in Figure 2 -A represent the hydrophobic regions in the PA cavity generated by GRID Force Field. 38 The presence of those regions in the PA cavity is in agreement with the findings of Liu et al. 39 , who described the existence of three hydrophobic pockets. Indeed, one hydrophobic pocket is generated by W706 and P411, and is responsible for the binding of P5 from PB1. The second hydrophobic pocket is due to P710 and L666 interactions, and it is responsible for the binding of F9 from PB1. Finally, L640, V636, M595, and W619 are responsible for the third hydrophobic pocket, where L8 of PB1 is located. An additional hydrophobic spot is located in the middle of the cavity and mainly generated by the aliphatic chain of E623 and the protein backbone. The most favorable FLAP docking pose in the PA cavity for compound 1, is shown in Figure 2 In addition, it must be noticed that, according to our modeling studies, all three compounds might be stabilized by a hydrogen bond between the oxygen of the C-2 amide group and the PA residue K643.
To conclusively determine the role that the simultaneous presence of both the aromatic rings at C-2 and C-3 positions plays on the biological activity, we synthesized the 2-amino derivative 19, which lacks the o-fluorobenzoyl moiety, and the primary amide 20, which lacks the C-3 pyridine ring. The ester and acid derivatives 21 and 22, analogues of 20, were also synthesized together with additional ethyl esters 23-26 and the corresponding acids 27-30, characterized by various substituents at the C-2 position.
Few modifications involved the cycloheptane ring, whose size was reduced to cyclohexane and cyclopentane as in compounds 31 and 32, the direct analogues of 1, as well as in the C-3 variously functionalized derivatives 33-36. However, the increased toxicity, especially of the cyclohexane derivatives, has discouraged the synthesis of further analogues. 
CHEMISTRY

RESULTS AND DISCUSSION
We started the study synthesizing and testing compound 1. The in-house synthesized 1 displayed biological activity comparable to that reported for the commercial derivative (compound 10 in reference 31). Indeed, it was endowed with a slightly lower PA-PB1 interaction inhibitory activity (IC50 = 145 µM) and a slightly higher anti-FluA activity in MDCK cells (EC50 = 90 µM); the inhouse synthesized 1 was used as comparative compound in all successive studies.
The whole set of derivatives were evaluated for their ability to inhibit the physical interaction between PA and PB1 subunits by ELISA assays, including the PB1( To exclude that the observed antiviral activities could be due to toxic effects in the target cells, all the synthesized compounds were tested by MTT assays in two cell lines, i.e., MDCK and HEK 293T (Table 1) . RBV, included again as a reference compound, showed a CC50 value > 250 μM in both cell lines, as previously reported. 51, 52 Looking at the activities shown in Table 1 , it clearly appears that in some cases, such as in compounds 4-6 and 17-19, the structural modifications improved the ability of the analogues to inhibit the PA-PB1 interaction. In particular, compounds 6 and 19 were the most potent with IC50
values of 32 and 35 μM, superimposable to that of the reference peptide. In addition, the 2-bycyclic derivatives 17 and 18, designed to improve the inhibitory efficiency of the hit 1 by increasing the hydrophobic interactions, defined by GRID MIFs, indeed proved to be better inhibitors, especially 17, which exhibited an inhibitory activity 3-fold higher than that of compound 1. This finding can also be considered a validation of the suggested binding pose for compound 1. According to the FLAP docking pose reported in Figure 2 , the different inhibitory activity among 1, 17, and 18 does not seem to correspond to a different binding mode of the compounds. However, considering that the three structures differ in the substituent at the C-2 position only, and that 17 possesses the most hydrophobic substituent in that position, this suggests that a stronger hydrophobic interaction could be the reason for a more difficult displacement of the compound, resulting in an increased activity.
Since the -FLAP-structure-based approach proved to be successful to retrieve -and optimize ligandprotein complexes, 31, 36 and in order to make a comparison with the binding modes hypothesized for the other PA/PB1 inhibitors, we inspected the possible FLAP docking poses for the most active compounds, 6 and 19, in the PA cavity; results are shown in Figure 3 . While for compounds 1, 17, and 18 reported in Figure 2 the most favorable poses were obtained upon interaction with the PA Xray conformation (i.e. structure 3CM8 after removal of PB1, thus in the most favorable pose for PB1 binding), the docking of 6 in the same cavity resulted to be unfavorable due to a steric hindrance between the p-chloro and the P710 residue, defining the second hydrophobic pocket.
However, the analysis of the flexibility of P710 based on the dynamic studies previously reported 31 showed that this residue can rotate when the PA-PB1 complex is not formed. At the same time, W706, which is not directly involved in PB1 binding but represents the bottom of the second hydrophobic cavity, can freely rotate to further enlarge this sub-pocket. Using a more relaxed snapshot of the PA structure, having the P710 and of W706 rotated to enlarge the second pocket (see Figure 3 -A), 6 results to retain a strong π-π interaction with W706 and the p-chlorophenyl group of derivative 6 can fit the enlarged second pocket (Figure 3 All the compounds able to inhibit PA-PB1 interaction were also active in inhibiting virus growth,
with EC50 values ranging from 18 μM for compound 6 to 61 μM for compound 18. In addition, many of the compounds synthesized in this study were surprisingly endowed with antiviral activity in the micromolar range and at nontoxic concentrations, although they were inactive in vitro as PA-PB1 inhibitors. Examining all the anti-influenza data reported in Table 1 Among all the synthesized compounds, p-chloro (compound 6), 2-amino (compound 19), and bicyclic derivatives (17 and 18), which exhibited the best inhibitory activity against both the PA-PB1 interaction and viral growth, were selected for further investigations including RBV as a control.
First we evaluated the effects of the compounds in virus yield assays, where all the them showed good antiviral activity (Table 2) proteins are coexpressed and interact with each other. (Table 3) , thus displaying broad-spectrum anti-influenza activity.
CONCLUSIONS
The viral RdRP is an attractive target to design new antivirals since it is highly conserved among Flu strains and no homologous has been found in mammalian cells. In particular, the disruption of its correct assembly through PPI inhibitors could be a promising strategy, although very few studies have been reported so far. Thanks to a SBDD approach, we recently identified a set of different small molecules able to disrupt PA-PB1 interaction and inhibit viral growth. In this study, some efforts have been pursued to evolve one of these molecules. Starting from thiophene-3-carboxamide An unexpected result coming from this study is the identification of many derivatives able to inhibit the viral growth without affecting PA-PB1 interaction in vitro. For these compounds, an alternative mechanism of action should exist and will be the object of future investigations.
In conclusion, the cycloheptathiophene-3-carboxamide scaffold, when properly functionalized, emerged as particularly suitable to impart anti-Flu activity.
EXPERIMENTAL SECTION
Computational methods. The design of larger compounds to optimize the hydrophobic interaction was performed using the FLAP approach 35 previously used to identify inhibitors of the PA-PB1
complex by virtual screening. 31 The FLAP software is developed and licensed by Molecular In this study, the main cavity of the crystallographic structure of a large C-terminal fragment of PA (aa 257-716) derived from the X-ray structure named 3CM8 28 was explored using the GRID force field. 38 Using the PA cavity as a template, the design of new possible inhibitors was performed using FLAP in the structure-based mode, 36, 37 evaluating the best pose among 50 conformers for each candidate, as previously reported 31 The probes used to generate the Molecular Interaction
Fields were H (shape), DRY (hydrophobic interactions), N1 (H-bond donor) and O (H-bond acceptor) interactions. A second snapshot of the PA in a more relaxed form was used to dock compound 6; the method used to generate the new conformation of PA was previously reported. 31 FLAP binding poses reported in this study underwent a mild optimization using Sybyl 2.0. Both ligand and surrounded PA residues were energy minimized using the Powell algorithm, with a convergence gradient ≤ 0.1 kcal/mol and a maximum of 5000 cycles.
Chemistry
All reactions were routinely checked by TLC on silica gel 60F254 (Merck) and visualized by using The physical-chemical properties are comparable to those of the commercial compound (STK063428) purchased from Vitas-M (Moscow, Russia) including the purity that is 100% for both the compounds, as assessed by UV chromatogram at 280 nm. 
166.5.
General procedure for C-2 amidation (Method B
)
2-(Benzoylamino)-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (2).
2-[(3-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (3).
The title compound was prepared starting from 19 by Method B, using 3-fluorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc.
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash chromatography eluting with EtOAc/cyclohexane (15%) and then crystallized by EtOH, to give 3 in 
2-[(4-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (4).
The title compound was prepared starting from 19 by Method B, using 4-fluorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc.
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash incubator. Successively, a solubilization solution was added to lyse cells. After 3 h of incubation at 37 °C, absorbance was measured at 620 nm using an ELISA plate reader (Tecan Sunrise™). Superiore di Sanita' (ISS), Rome, Italy.
2-(4-Chlorobenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (6)
.
Plaque reduction assays (PRA)
Table of Contents
Elemental Analysis data for target compounds 1-24, 26-32, and 36 S2 Figure S1 . FLAP binding poses for compounds 2, 4 and 5 S3 Table S1 . Elemental analysis data for target compounds 
